You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,106,021


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,106,021
Title:Benzylbenzene derivatives and methods of use
Abstract:Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
Inventor(s):Chen Yuanwei, Cheng Huawei, Li Shengbin, Wu Yuelin, Feng Yan, Lv Binhua, Xu Baihua, Seed Brian, Hadd Michael J., Song Yanli, Du Jiyan, Wang Congna, Roberge Jacques Y.
Assignee:Theracos, Inc.
Application Number:US12917367
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,106,021
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,106,021: A Comprehensive Analysis

Introduction

Patents are crucial for protecting intellectual property and encouraging innovation. The United States Patent 8,106,021, like any other patent, has specific claims and a defined scope that determine its validity and enforceability. This article delves into the details of this patent, exploring its claims, the patent landscape, and the relevant legal frameworks that govern its interpretation.

Patent Claims: Definition and Importance

Patent claims are the heart of a patent, defining the scope of the invention and what is protected by the patent. They are found in the claims section of the patent document and must be clear, concise, and supported by the specification[2].

United States Patent 8,106,021: Overview

To analyze the scope and claims of U.S. Patent 8,106,021, one must first identify the invention it covers. This patent, assuming it is similar to others in its field, would typically include a detailed specification and a set of claims that outline the novel and non-obvious aspects of the invention.

Specification

The specification section of the patent provides background information, describes the invention in detail, and includes examples of how to make and use the invention. This section is essential for understanding the context and limitations of the claims[2].

Claims

The claims section is where the legal boundaries of the patent are defined. Claims can be independent or dependent, with independent claims standing alone and dependent claims referring back to an independent claim. The clarity and breadth of these claims are critical in determining the patent's scope[3].

Claim Construction and Interpretation

Claim construction is the process of determining the meaning and scope of the claims. This process involves interpreting the language of the claims in light of the specification and any relevant prior art. The Federal Circuit has established that statements of intended purpose in the preamble of a claim can be limiting if they provide essential elements of the invention[4].

Functional Elements in Claims

Functional elements in claims, which describe what the invention does rather than how it is made, can be particularly complex. These elements must be supported by the specification to ensure that the claims are not overly broad or vague[2].

Patent Scope and Breadth

The scope of a patent is a measure of how broadly or narrowly the claims cover the invention. Metrics such as independent claim length and independent claim count can be used to measure patent scope. Narrower claims are often associated with a higher probability of grant and a shorter examination process[3].

Patent Term Adjustment (PTA) and Patent Term Extension (PTE)

Patents can have their term extended through Patent Term Adjustment (PTA) or Patent Term Extension (PTE). PTA is granted to compensate for delays in the patent office, while PTE is granted to compensate for regulatory delays, such as those required by the FDA for drug approvals[5].

Obviousness-Type Double Patenting (ODP)

ODP is a doctrine that prevents the extension of patent term beyond the statutory 20 years from the earliest priority filing date by claiming obvious variants of an earlier patent. The calculation of expiration dates, including any PTA or PTE, is crucial in determining potential unpatentability under ODP. For patents with PTA, the adjusted expiration date after adding PTA is used in ODP analysis, whereas for patents with PTE, the original expiration date before PTE is used[1].

Regulatory Environment

For patents related to human drug products, medical devices, or other regulated products, the FDA plays a significant role in the Patent Term Restoration Program. This program extends the patent term to compensate for the time lost during regulatory review, ensuring that patent holders have sufficient time to market their products[5].

FDA’s Role

The FDA assists the Patent and Trademark Office (PTO) in determining a product’s eligibility for patent term restoration and provides information on the regulatory review period. The PTO is responsible for determining the period of patent extension[5].

Patent Landscape

The patent landscape surrounding U.S. Patent 8,106,021 includes other patents in the same field, prior art, and any ongoing litigation or disputes. Understanding this landscape is essential for assessing the patent’s validity and potential for enforcement.

Prior Art and Novelty

The novelty of the invention claimed in U.S. Patent 8,106,021 must be assessed against prior art. Any prior art that anticipates or renders the claims obvious can affect the patent’s validity[2].

Litigation and Disputes

Patent litigation often revolves around claim construction, infringement, and validity. The decisions in such cases can significantly impact the scope and enforceability of the patent[4].

Conclusion

Understanding the scope and claims of U.S. Patent 8,106,021 involves a detailed analysis of the patent document, the legal frameworks governing patent law, and the regulatory environment. Here are the key points:

  • Claims Definition: Claims define the scope of the invention and must be clear and supported by the specification.
  • Claim Construction: Claims are interpreted in light of the specification and prior art.
  • Patent Scope: Metrics like independent claim length and count help measure patent scope.
  • PTA and PTE: These mechanisms extend patent terms but are treated differently in ODP analysis.
  • Regulatory Environment: The FDA plays a crucial role in patent term restoration for regulated products.
  • Patent Landscape: Understanding prior art, litigation, and disputes is essential for assessing patent validity.

Key Takeaways

  • Clear Claims: Ensure claims are clear, concise, and supported by the specification.
  • Regulatory Compliance: For regulated products, understand the role of the FDA in patent term restoration.
  • ODP Analysis: Calculate expiration dates correctly, considering PTA and PTE differently.
  • Patent Scope Metrics: Use metrics like claim length and count to assess patent scope.
  • Litigation Awareness: Be aware of ongoing litigation and disputes in the patent landscape.

FAQs

Q: What is the primary purpose of patent claims?

A: The primary purpose of patent claims is to define the scope of the invention and what is protected by the patent.

Q: How does the FDA contribute to the Patent Term Restoration Program?

A: The FDA assists the PTO in determining a product’s eligibility for patent term restoration and provides information on the regulatory review period.

Q: What is the difference between PTA and PTE in the context of ODP?

A: PTA and PTE are treated differently in ODP analysis; PTA adjusts the expiration date after its addition, while PTE uses the original expiration date before its addition.

Q: Why is claim construction important?

A: Claim construction is crucial because it determines the meaning and scope of the claims, which can affect the patent’s validity and enforceability.

Q: How do metrics like independent claim length and count help in assessing patent scope?

A: These metrics provide a quantifiable way to measure patent scope, with narrower claims often associated with a higher probability of grant and a shorter examination process.

Sources

  1. Patent Term Adjustment and Patent Term Extension Analyzed Differently in Consideration of Obviousness-Type Double Patenting. Duane Morris.
  2. Functional Elements in Patent Claims, as Construed by the Patent Trial and Appeal Board (PTAB). University of Illinois at Chicago.
  3. Patent Claims and Patent Scope. SSRN.
  4. Eli Lilly and Company v. Teva Pharmaceuticals. U.S. Court of Appeals for the Federal Circuit.
  5. Frequently Asked Questions on the Patent Term Restoration Program. FDA.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,106,021

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Theracosbio BRENZAVVY bexagliflozin TABLET;ORAL 214373-001 Jan 20, 2023 RX Yes Yes 8,106,021 ⤷  Subscribe AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.